- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05905575
A Family Dyad-focused Diabetes Self-Management Intervention for African American Adults
A Family Dyad-focused Diabetes Self-Management Intervention for African American Adults With Type 2 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University College of Nursing
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Individual with type 2 diabetes:
- Self-identification as African American;
- 40 years or older
- Type 2 diabetes diagnosis for at least six months;
- A1c > 7.0% at time of enrollment;
- Being able to speak and read English;
- Being able to walk;
- Having an adult family member/close friend willing to co-participate in the study.
Family members:
- Adults (18 years or older, with or without T2D);
- Residing in the same household as the T2D participants;
- Being a spouse, adult child or sibling; or close friend
- Being able to walk;
- Being able to speak and read English.
Exclusion Criteria:
Individual with T2D and family members:
- Being pregnant or have an advanced or terminal condition;
- Being cognitively impaired or unable to provide informed consent;
- Lack conclusive evidence of T2D for patients with T2D.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control
All control participants will receive usual care from their primary healthcare provider.
A condensed family dyad diabetes intervention will be delivered to the control participants by the end of the study.
|
|
|
Experimental: Intervention
Patient-family member dyads in the family dyad intervention arm will receive 1) 10 sessions (8 weekly and 2 biweekly) over 12 weeks of family-dyad-focused, virtual group sessions on diabetes self-management and family support; 2) family dyad-focused support component in each group session; and 3) individual family feedback telephone sessions.
|
The goals of the intervention are to encourage participants to (1) daily self-manage diabetes and stress; (2) establish a healthy eating pattern; (3) engage in brisk walking of 150 or more minutes a week; and (4) use solution-focused problem-solving strategy and supportive family communication skills.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in diabetes control
Time Frame: Baseline (T1) to immediate post-intervention at month 5 (T2)
|
Change in glycosylated hemoglobin A1c will be measured with finger stick blood with a glycosylated hemoglobin A1CNow+ test.
Changes in average percent of A1c will be used in the study.
|
Baseline (T1) to immediate post-intervention at month 5 (T2)
|
|
Change in diabetes control
Time Frame: Baseline (T1) to six months after intervention (T3) at month 11
|
Change in glycosylated hemoglobin A1c will be measured with finger stick blood with a glycosylated hemoglobin A1CNow+ test.
Changes in average percent of A1c will be used in the study.
|
Baseline (T1) to six months after intervention (T3) at month 11
|
|
Change in health-related quality of life
Time Frame: Baseline (T1) to immediate post-intervention at month 5 (T2)
|
Patient-Reported Outcomes Measurement Information System Global Health (PROMIS 10) will be used to measure changes in total scores of the global physical and global mental health.
Scores range from 0-100 with higher scores indicating better quality of life.
|
Baseline (T1) to immediate post-intervention at month 5 (T2)
|
|
Change in health-related quality of life
Time Frame: Baseline (T1) to six months after intervention (T3) at month 11
|
Patient-Reported Outcomes Measurement Information System Global Health (PROMIS 10) will be used to measure changes in total scores of the global physical and global mental health.
Scores range from 0-100 with higher scores indicating better quality of life.
|
Baseline (T1) to six months after intervention (T3) at month 11
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in blood pressure control
Time Frame: Baseline (T1) to immediate post-intervention at month 5 (T2)
|
Change in blood pressure will be measured with average scores of systolic and diastolic pressures.
|
Baseline (T1) to immediate post-intervention at month 5 (T2)
|
|
Change in blood pressure control
Time Frame: Baseline (T1) to six months after intervention (T3) at month 11
|
Change in blood pressure will be measured with average scores of systolic and diastolic pressures.
|
Baseline (T1) to six months after intervention (T3) at month 11
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023 H0010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Requests will be reviewed by the project investigators (PI). In accordance with NIH policies and procedures regarding data use and data sharing, user registration will be required to access the les. Users must agree to the conditions of use governing access to the public release data, including restrictions against attempting to identify study participants, destruction of the data after analyses are completed, reporting responsibilities, restrictions on redistributions of the data to third parties, and proper acknowledgement of the data resource. Any presentations, abstracts, or publications must include an acknowledgement/reference of the research team.
The requesting researcher(s) will be notified that they may only use the data for the purposes for which the data were requested and only by the individuals listed in the request. The requesting researcher(s) will be responsible for notifying the PI upon completion of analysis indicating the way the data were destroyed.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.